

George Hruby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9189199/publications.pdf>

Version: 2024-02-01

110
papers

4,338
citations

117625

34
h-index

114465

63
g-index

110
all docs

110
docs citations

110
times ranked

5479
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Comparison of ¹⁸ F-Fluoromethylcholine Versus ⁶⁸ Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1185-1190.	5.0	516
2	The Impact of ⁶⁸ Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 82-88.	5.0	281
3	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.9	270
4	⁶⁸ Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. <i>BJU International</i> , 2016, 117, 732-739.	2.5	239
5	Treatment Outcomes from ⁶⁸ Ga-PSMA PET/CT-“Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1972-1976.	5.0	149
6	Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial ⁶⁸ Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. <i>Journal of Nuclear Medicine</i> , 2019, 60, 950-954.	5.0	133
7	Desmoplastic neurotropic melanoma. <i>Cancer</i> , 2008, 113, 2770-2778.	4.1	131
8	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology Oncology</i> , 2018, 1, 531-537.	5.4	106
9	Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. <i>Annals of Surgical Oncology</i> , 2007, 14, 1943-1952.	1.5	101
10	The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 3574-3581.	1.5	98
11	Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2509-2518.	1.5	95
12	3-Year Freedom from Progression After ⁶⁸ Ga-PSMA PET/CT-“Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 866-872.	5.0	86
13	Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 389.	2.2	84
14	PSA doubling time of prostate carcinoma managed with watchful observation alone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 615-620.	0.8	81
15	Diagnostic accuracy of ⁶⁸ Ga-prostate-specific membrane antigen (⁶⁸ Ga-PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ⁶⁸ Ga-PSMA PET to mpMRI. <i>BJU International</i> , 2019, 124, 43-49.	2.5	80
16	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3141.	1.6	78
17	The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. <i>Psycho-Oncology</i> , 2013, 22, 2557-2564.	2.3	65
18	Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 674-680.	0.8	63

#	ARTICLE	IF	CITATIONS
19	Oxidative stress in prostate cancer patients: A systematic review of case control studies. <i>Prostate International</i> , 2016, 4, 71-87.	2.3	63
20	Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. <i>BMC Cancer</i> , 2011, 11, 142.	2.6	62
21	Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. <i>Radiotherapy and Oncology</i> , 2004, 71, 259-265.	0.6	61
22	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3325-3334.	1.5	59
23	(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 269-276.	0.8	58
24	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , 2016, 10, 223-233.	2.9	57
25	Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 138-143.	0.8	48
26	Clinical Trials of a Urethral Dose Measurement System in Brachytherapy Using Scintillation Detectors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 609-615.	0.8	46
27	Prospective patient-based assessment of effectiveness of palliative radiotherapy for bone metastases. <i>Radiotherapy and Oncology</i> , 2001, 61, 77-82.	0.6	43
28	The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. <i>Radiotherapy and Oncology</i> , 2014, 111, 316-320.	0.6	42
29	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	2.1	41
30	Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. <i>Radiotherapy and Oncology</i> , 2011, 101, 490-494.	0.6	40
31	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.6	39
32	Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 99-102.	0.6	38
33	Mild, Moderate, or Severe Pain Categorized by Patients with Cancer with Bone Metastases. <i>Journal of Palliative Medicine</i> , 2006, 9, 850-854.	1.1	37
34	Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1172-1178.	0.8	36
35	Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. <i>BMC Cancer</i> , 2019, 19, 674.	2.6	34
36	Prospective Assessment of Symptom Palliation for Patients Attending a Rapid Response Radiotherapy Program. <i>Journal of Pain and Symptom Management</i> , 2001, 22, 649-656.	1.2	33

#	ARTICLE	IF	CITATIONS
37	Validation of the English version of the Trust in Oncologist Scale (TiOS). Patient Education and Counseling, 2013, 91, 25-28.	2.2	33
38	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 530-538.	0.8	33
39	Prospective analysis of the utility of ¹⁸ F-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, ^{TROC} 09:03. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 412-419.	1.8	31
40	⁶⁸ Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 343-346.	1.1	30
41	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. Cancers, 2021, 13, 4824.	3.7	29
42	Surgical and oncology trials for rectal cancer: Who will participate?. Surgery, 2007, 142, 94-101.e20.	1.9	28
43	Delineating sites of failure following post-prostatectomy radiation treatment using ⁶⁸ Ga-PSMA-PET. Radiotherapy and Oncology, 2018, 126, 244-248.	0.6	27
44	A Comparison of Radiation Therapy Outcomes of Bone Metastases Employing International Consensus Endpoints and Traditional Endpoints. Supportive Cancer Therapy, 2004, 1, 173-178.	0.3	25
45	The Impact of Preradiation Residual Disease Volume on Time to Locoregional Failure in Cutaneous Merkel Cell Carcinoma—A TROG Substudy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 91-95.	0.8	25
46	Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer, 2015, 15, 281.	2.6	22
47	Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. Journal of Medical Radiation Sciences, 2017, 64, 25-34.	1.5	22
48	FDG-PET parameters predict for recurrence in anal cancer — results from a prospective, multicentre clinical trial. Radiation Oncology, 2019, 14, 140.	2.7	22
49	Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets. Advances in Radiation Oncology, 2019, 4, 191-200.	1.2	22
50	Diagnostic Computed Tomography Enabled Planning for Palliative Radiation Therapy: Removing the Need for a Planning Computed Tomography Scan. Practical Radiation Oncology, 2021, 11, e146-e153.	2.1	22
51	Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results. International Journal of Radiation Oncology Biology Physics, 2018, 101, 387-395.	0.8	21
52	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.6	20
53	Radiation treatment in recurrent squamous cell cancer of the vulva. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1193-1197.	0.8	18
54	Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. Clinical Oncology, 2019, 31, 108-114.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1015-1024.	0.8	18
56	Combined large cell neuroendocrine carcinoma and spindle cell carcinoma of the lung. <i>Annals of Diagnostic Pathology</i> , 2001, 5, 240-245.	1.3	17
57	HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 220-226.	1.8	17
58	Cardiac Metastasis in Merkel Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e52-e53.	1.6	15
59	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. <i>BMC Research Notes</i> , 2015, 8, 192.	1.4	15
60	High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity. <i>Brachytherapy</i> , 2015, 14, 670-676.	0.5	15
61	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. <i>Cancers</i> , 2021, 13, 2353.	3.7	15
62	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021, 11, 706331.	2.8	15
63	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021, 45, 394-404.	3.7	15
64	The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. <i>Medical Physics</i> , 2019, 46, 4725-4737.	3.0	14
65	Results of a Prospective Dose Escalation Study of Linear Accelerator-Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 623-630.	1.2	14
66	Quality of Life after Local External Beam Radiation Therapy for Symptomatic Bone Metastases: A Prospective Evaluation. <i>Supportive Cancer Therapy</i> , 2004, 1, 179-184.	0.3	12
67	The Role of Sentinel Lymph Node Biopsy in Patients with Merkel Cell Carcinoma: Uncertainty Prevails. <i>Annals of Surgical Oncology</i> , 2014, 21, 1517-1519.	1.5	12
68	Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).. <i>Journal of Clinical Oncology</i> , 2020, 38, 485-485.	1.6	12
69	Identifying and prioritising gaps in colorectal cancer trials research in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 507-511.	1.7	11
70	Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and <sc>European Association of Urology</sc> biochemical recurrence risk groups. <i>BJU International</i> , 2022, 130, 32-39.	2.5	11
71	Malignant retroperitoneal paraganglioma: Case report and review of treatment options. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2000, 44, 478-482.	0.6	10
72	Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial. <i>Radiotherapy and Oncology</i> , 2020, 151, 234-241.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Introducing Computed Tomography Simulationâ€‘Free and Electronic Patient-Reported Outcomesâ€‘Monitored Palliative Radiation Therapy into Routine Care: Clinical Outcomes and Implementation Experience. <i>Advances in Radiation Oncology</i> , 2021, 6, 100632.	1.2	10
74	Patient Expectation of the Partial Response and Response Shift in Pain Score. <i>Supportive Cancer Therapy</i> , 2007, 4, 110-118.	0.3	9
75	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018, 17, 458-466.	2.0	9
76	A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 144, 7-12.	0.6	9
77	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	1.0	8
78	Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. <i>Practical Radiation Oncology</i> , 2022, 12, e201-e206.	2.1	8
79	<scp>S</scp>entinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in <scp>M</scp>erkel cell carcinoma: A pilot case series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 353-359.	1.8	7
80	Developing knowledgeâ€‘based planning for gynaecological and rectal cancers: a clinical validation of RapidPlan â„¢. <i>Journal of Medical Radiation Sciences</i> , 2020, 67, 217-224.	1.5	7
81	Patientsâ€™ experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. <i>Brachytherapy</i> , 2011, 10, 395-400.	0.5	6
82	Constrainedâ€‘beam inverse planning for intensityâ€‘modulated radiation therapy of prostate cancer patients with bilateral hip prostheses. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 703-707.	1.8	6
83	Quality improvement process to assess tattoo alignment, setâ€‘up accuracy and isocentre reproducibility in pelvic radiotherapy patients. <i>Journal of Medical Radiation Sciences</i> , 2014, 61, 246-252.	1.5	6
84	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. <i>Annals of Surgical Oncology</i> , 2018, 25, 3476-3482.	1.5	6
85	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 957-963.	0.8	5
86	Implementing daily soft tissue image guidance with reduced margins for postâ€‘prostatectomy radiotherapy: researchâ€‘based changes to clinical practice. <i>Journal of Medical Radiation Sciences</i> , 2019, 66, 259-268.	1.5	5
87	Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy. <i>Radiation Oncology</i> , 2021, 16, 20.	2.7	5
88	Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality. <i>Journal of Contemporary Brachytherapy</i> , 2014, 4, 344-349.	0.9	4
89	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. <i>Trials</i> , 2019, 20, 477.	1.6	4
90	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. <i>Annals of Surgical Oncology</i> , 2019, 26, 315-317.	1.5	4

#	ARTICLE	IF	CITATIONS
91	Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. <i>Brachytherapy</i> , 2011, 10, 454-460.	0.5	3
92	Complications of prostate cancer treatment. <i>Lancet Oncology</i> , The, 2014, 15, e149-e150.	10.7	3
93	78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e356-e363.	1.1	3
94	Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. <i>Case Reports in Oncology</i> , 2018, 11, 756-762.	0.7	3
95	Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: A multicentre observational study. <i>ANZ Journal of Surgery</i> , 2021, 91, 2447-2452.	0.7	3
96	Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. <i>Radiotherapy and Oncology</i> , 2021, 162, 91-97.	0.6	3
97	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9500-9500.	1.6	3
98	Reirradiation for recurrent pterygia. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 635.	0.8	2
99	Long-Term Follow-Up of Patients Treated with Intermittent Hormone Therapy for Advanced Prostate Cancer. <i>Prostate Journal</i> , 1999, 1, 138-143.	0.2	2
100	Patient-reported outcome measures (PROMs) in routine care palliative radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 154, e10-e11.	0.6	2
101	Contemporary salvage post prostatectomy radiotherapy: Early implementation improves biochemical control. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 240-247.	1.8	1
102	A simple algorithm to predict non-compliance with organ at risk dose-volume constraints when planning intensity modulated post-prostatectomy radiation treatment: "Why we should put the CART before the horse". <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 546-551.	1.8	1
103	Clinical impact of PET imaging in prostate cancer management. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 649-653.	1.8	1
104	Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma. <i>Oxford Medical Case Reports</i> , 2022, 2022, omac012.	0.4	1
105	Prostate adenocarcinoma with mucinous features " is it PSMA avid?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	1.8	0
106	Radiation in the Management of Primary and Regional Merkel Cell Carcinoma. <i>Modular Medicine and Medicinal</i> , 2010, , 229-238.	0.4	0
107	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre.. <i>Journal of Clinical Oncology</i> , 2017, 35, 395-395.	1.6	0
108	A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS263-TPS263.	1.6	0

#	ARTICLE	IF	CITATIONS
109	In Regard to Roos et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 260-261.	0.8	0
110	Don't throw the baby out with the bath water. Prostate, 2022, 82, 397-398.	2.3	0